Current role of radiomics and radiogenomics in predicting oncological outcomes in bladder cancer

Abstract

Background: Radiomics refers to the conversion of medical images into high-throughput, quantifiable data to analyze disease patterns, aid decision-making, and predict prognosis. Radiogenomics is an extension of radiomics and involves a combination of conventional radiomics techniques with molecular analysis in the form of genomic and transcriptomic data. In the field of bladder cancer, studies have investigated the development, implementation, and efficacy of radiomic and radiogenomic nomograms in predicting tumor grade, gene expression, and oncological outcomes, with variable results. We aimed to perform a systematic review of the current literature to investigate the development of a radiomics-based nomogram to predict oncological outcomes in bladder cancer.

Materials and methods: The Medline, EMBASE, and Web of Science databases were searched up to February 17, 2023. Gray literature was also searched to further identify other suitable publications. Quality assessment of the included studies was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 and Radiomics Quality Score.

Results: Radiogenomic nomograms generally had good performance in predicting the primary outcome across the included studies. The median area under the curve, sensitivity, and specificity across the included studies were 0.83 (0.63-0.973), 0.813, and 0.815, respectively, in the training set and 0.75 (0.702-0.838), 0.723, and 0.652, respectively, in the validation set.

Conclusions: Several studies have demonstrated the predictive potential of radiomic and radiogenomic models in advanced pelvic oncology. Further large-scale studies in a prospective setting are required to further validate results and allow generalized use in modern medicine.

Keywords

Radiomics / Radiogenomics / Oncology / Bladder cancer / Survival / Recurrence / Treatment response

Acknowledgments

None.

Statement of ethics

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline and was registered on PROSPERO, with a registry number of CRD42023396249.

Conflict of interest statement

The authors report no conflict of interest.

Funding source

This research was supported by the Joly Leadership Fund.

Author contributions

NOS, HT, AC, PL, JM, MK: Conceptualization;

NOS, HT, AC: Data curation;

NOS, HT: Formal analysis;

AC, PL, JM, MK: Supervision;

NOS, HT, AC, PL, JM, MK: Writing—original draft, writing—review and editing.

Data availability

The datasets generated during and/or analyzed during the current study are publicly available. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

References

[1] Guiot J, Vaidyanathan A, Deprez L, et al. A review in radiomics: Making personalized medicine a reality via routine imaging. Med Res Rev 2022; 42(1):426-440.

[2] Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. Radiology 2016; 278(2):563-577.

[3] Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14(12):749-762.

[4] PelvEx Collaborative. Contemporary management of locally advanced and recurrent rectal cancer: Views from the PelvEx Collaborative. Cancers (Basel) 2022; 14(5):1161.

[5] Lo Gullo R, Daimiel I, Morris EA, Pinker K. Combining molecular and imaging metrics in cancer: Radiogenomics. Insights Imaging 2020; 11(1):1.

[6] Pinker K, Shitano F, Sala E, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging 2018; 47(3):604-620.

[7] Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: A systematic review. Int J Radiat Oncol Biol Phys 2018; 102(4):1143-1158.

[8] Xue C, Yuan J, Lo GG, et al. Radiomics feature reliability assessed by intraclass correlation coefficient: A systematic review. Quant Imaging Med Surg 2021; 11(10):4431-4460.

[9] Feng C, Zhou Z, Huang Q, Meng X, Li Z, Wang Y. Radiomics nomogram based on high-b-value diffusion-weighted imaging for distinguishing the grade of bladder cancer. Life (Basel) 2022; 12(10):1510.

[10] Zheng Z, Gu Z, Xu F, et al. Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer. Cancer Imaging 2021; 21(1):65.

[11] Zhang S, Song M, Zhao Y, et al. Radiomics nomogram for preoperative prediction of progression-free survival using diffusion-weighted imaging in patients with muscle-invasive bladder cancer. Eur J Radiol 2020;131:109219.

[12] Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349(9):859-866.

[13] Bhindi B, Frank I, Mason RJ, et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: A pathologic stage-matched analysis. Eur Urol 2017; 72(5):660-664.

[14] Choi SJ, Park KJ, Heo C, Park BW, Kim M, Kim JK. Radiomics-based model for predicting pathological complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin Radiol 2021; 76(8):627.e13-627.e21.

[15] Cunneen C, Kelly M, Nason G, Ryan E, Creavin B, Winter D. The role of exenterative surgery in advanced urological neoplasms. Curr Urol 2020; 14(2):57-65.

[16] Covidence Systematic Review Software. Veritas Health Innovation, Melbourne, Australia.

[17] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8):529-536.

[18] Lin P, Wen DY, Chen L, et al. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. Eur Radiol 2020; 30(1):547-557.

[19] Parmar A, Qazi AA, Stundzia A, et al. Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Can Urol Assoc J 2022; 16(3):E113-E119.

[20] Qian J, Yang L, Hu S, et al. Feasibility study on predicting recurrence risk of bladder cancer based on radiomics features of multiphase CT images. Front Oncol 2022;12:899897.

[21] Woźnicki P, Laqua FC, Messmer K, et al. Radiomics for the prediction of overall survival in patients with bladder cancer prior to radical cystectomy. Cancers (Basel) 2022; 14(18):4449.

[22] Xu X, Wang H, Du P, et al. A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors. J Magn Reson Imaging 2019; 50(6):1893-1904.

[23] Zhang X, Wang Y, Zhang J, Zhang L, Wang S, Chen Y. Development of a MRI-based radiomics nomogram for prediction of response of patients with muscle-invasive bladder cancer to neoadjuvant chemotherapy. Front Oncol 2022;12:878499.

[24] van Hauen MB, Maibom SL, Thind PO, Martin Poulsen A, Joensen UN, Røder MA. Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer. Scand J Urol 2022; 56(2):149-154.

[25] Novotny V, Hakenberg OW, Wiessner D, et al. Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 2007; 51(2):397-401 discussion 401-402.

[26] Konety BR, Allareddy V, Herr H. Complications after radical cystectomy: Analysis of population-based data. Urology 2006; 68(1):58-64.

[27] Mari A, Campi R, Tellini R, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: A comprehensive review of the literature. World J Urol 2018; 36(2):157-170.

[28] Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55(1):164-174.

[29] Kozikowski M, Suarez-Ibarrola R, Osiecki R, et al. Role of radiomics in the prediction of muscle-invasive bladder cancer: A systematic review and meta-analysis. Eur Urol Focus 2022; 8(3):728-738.

[30] Qu J, Shen C, Qin J, et al. The MR radiomic signature can predict preoperative lymph node metastasis in patients with esophageal cancer. Eur Radiol 2019; 29(2):906-914.

[31] Park BW, Kim JK, Heo C, Park KJ. Reliability of CT radiomic features reflecting tumour heterogeneity according to image quality and image processing parameters. Sci Rep 2020; 10(1):3852.

[32] Rizzo S, Botta F, Raimondi S, et al. Radiomics: The facts and the challenges of image analysis. Eur Radiol Exp 2018; 2(1):36.